- Start date: -
- End date: -
- Value: -
Untreated tooth decay is the most common disease world-wide. Following the successful spin out of Leeds’ “Filling without Drilling” patent-protected self-assembling peptide (SAP) technology for treatment of early tooth decay (caries) pre-2014, three new SAP products are now available for treating tooth sensitivity and caries prevention. Two further products will be launched this year. The company formed to market Leeds’ technology has won 2 major awards, grown in size and turnover and are introducing a new product line treating periodontal disease (gum disease); the sixth most common of all diseases, in the near future.
Advancing the Genetics of Enamel Developmental Abnormalities (AGEnDA): Enamel is the hardest substance in the human body and is designed to last a lifetime even though it has no capacity for cellular repair. Through the investigation of families with amelogenesis imperfecta (AI) – a heterogeneous group of inherited enamel defects – the Leeds team has established a world-leading reputation for discovery of genetic variants that are critical to normal enamel formation. The translation of genetic research discoveries to NHS patient care has started through successful application to the UK Genetic Testing Network (dossier #331 amelogenesis imperfecta 21 Gene Panel). This is a first for clinical dentistry and paves the way for defining patient pathways and raising standards of care.